{"id":"W2556217933","doi":"10.1182/blood.v112.11.lba-1.lba-1","title":"Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre","funders":"","keywords":"Fludarabine; Medicine; Rituximab; Internal medicine; Tolerability; Clinical endpoint; Regimen; Progression-free survival; Gastroenterology; Refractory (planetary science); Cyclophosphamide; Surgery; Randomized controlled trial; Oncology; Chemotherapy; Adverse effect; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003655771,0.001337276,0.002193585,0.0004039343,0.0003671719,0.0009907958,0.0007964388,0.001249045,0.002778002],"category_scores_gemma":[0.001708821,0.0004346829,0.001782599,0.0004052099,0.001036488,0.0009120356,0.0005318485,0.002468148,0.0004836144],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007205523,"about_ca_system_score_gemma":0.0007764902,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000693422,"about_ca_topic_score_gemma":0.001780729,"domain_scores_codex":[0.9989498,0.000702868,0.0000634171,0.00009718341,0.00007625671,0.0001104516],"domain_scores_gemma":[0.9986445,0.0004240462,0.000338533,0.00009198705,0.00005267919,0.0004480832],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9724957,0.005437194,0.001066798,0.0003275854,0.001046116,0.0000318121,0.00005350131,0.0003893694,0.002504118,0.00008246602,0.0009715348,0.0155937],"study_design_scores_gemma":[0.8171715,0.1740618,0.004892502,0.00005933957,0.001311004,0.0000939868,0.00003677099,0.0005055373,0.0006157932,0.000156203,0.001072371,0.00002328691],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904482,0.005764536,0.0003187946,0.0004699749,0.0001953246,0.000796072,0.0005399466,0.00007350087,0.00139374],"genre_scores_gemma":[0.9897361,0.003654271,0.0008771213,0.0009505416,0.0004767179,0.001384584,0.001542563,0.00002319836,0.001355109],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003655771,"threshold_uncertainty_score":0.01933384,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03445272499857231,"score_gpt":0.3069382083251383,"score_spread":0.272485483326566,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}